Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

at 6 months, p=0.015) and improved functional capacity (gain of 52.6 meters over 6 minutes' walk compared with controls at 12 months, p=0.06).

After 12 months, 40% of all treated patients had reverted to class I NYHA status compared with 14% of all controls, and this effect remained when patients were matched for the presence of class II status at baseline. The group who received the 25M MPC dose showed a significant 8.9 point improvement in ejection fraction over controls at 3 months (p=0.008), with a sustained but less pronounced effect over 12 months. In contrast, the group who received 150M MPC did not show improved ejection fraction, suggesting that the positive effects of this dose on clinical outcomes, remodeling, and functional capacity may be due to other mechanisms such as anti-fibrosis.

"These clinical findings are the first using any cell therapy in heart failure patients to show a concordant positive effect on clinical outcomes, cardiac remodelling, and functional capacity, the three key parameters in congestive heart failure.  Together, they indicate that a single 150 million dose of Revascor™ may significantly reduce both heart failure hospitalizations and death in these very sick patients who have such a poor prognosis despite maximal existing therapies," Dr Perin said.  

"Based on their defined product characterization, batch to batch consistency, immediate availability, and lack of clinically relevant immunogenicity, MPCs appear to be an ideal cell type to provide a new level of patient care in congestive heart failure.  We look forward to progressing the Revascor™ clinical program into Phase 3," Dr Perin added.

Revascor™ is being jointly developed by Mesoblast and its strategic alliance partner, Teva Pharmaceutical Industries Ltd.  

Teva's Corporate Vice President Global Branded Products, Kevin Buchi, said: "These independently-reviewed results serve to reinforce Teva's commi
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... -- LifeScienceIndustryResearch.com announces Global Angiographic X-ray ... pages along with 8 company profiles added to ... 2015 Market Research Report on Global Angiographic X-ray ... report on Global Angiographic X-ray System market.  For ... basic information including definition, classification, application, industry chain ...
(Date:3/1/2015)... WASHINGTON , March 1, 2015  USPlabs ... of the following and states that media reports ... false: On Saturday, February 28, 2015, ... issued a Public Notification on the contamination of ... Super Thermogenic (referred to below as "OEP") with ...
(Date:2/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a leading ... pharmaceutical, biotechnology, and medical device industries with operations in ... United States , congratulates our partner TaiMed Biologics ... for ibalizumab (TMB355). The FDA designates a drug as ... in combination with one or more other drugs, to ...
Breaking Medicine Technology:Global Angiographic X-ray System Industry Research Report 2Global Angiographic X-ray System Industry Research Report 3Global Angiographic X-ray System Industry Research Report 4Global Angiographic X-ray System Industry Research Report 5OEP Product Is Counterfeit 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2
... 2011 Raylene Riha and her husband, Michael, filed ... Johnson, Inc. seeking compensation for injuries caused by failures ... that have been recalled.  John David Hart of the ... Texas, is the attorney representing Raylene and Michael Riha ...
... (Tianjin) Co. Ltd, a leading research-based contract manufacturer of advanced ... the U.S. and China, is pleased to announce the recent ... Assurance as of March 1, 2011. Mr. ... the pharmaceutical industry (early and late stage), in quality assurance ...
Cached Medicine Technology:Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman 2Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance 2
(Date:3/1/2015)... March 01, 2015 Ticket Down is a ... Chicago at Soldier Field. Deadheads have been anxiously ... January. , Grateful Dead was formed 50 years ago back ... together as one until the untimely death of Jerry Garcia ... different genres including blues, reggae, rock, bluegrass, folk, space rock ...
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:3/1/2015)... 2015 CrossFit Attollo is a CrossFit gym ... a special discount to new members. Now through the ... three month contract will receive their fourth month half off. ... members $440. The three month contract is only $264, ... the fourth month comes in at only $55. The special ...
(Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
(Date:2/28/2015)... With their commitment to achieving physical ... additional exercise to their already robust library of oblique ... commonly known as, is often performed on a stationary ... in a relatively safe manner and can be performed ... full description of “Rope Pulls” is located in the ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... last 25 years, in New York, there has been a ... has increased. Researchers at the University of Texas, have analysed ... between 1981 and 1999.// They find there has been a ... 2.0 cases per 150,000 population to 12.2 per 100,000. For ...
... some valuable advice on how to make sure your vitamin ... and teeth, and helps prevent osteoporosis and any bone related ... vitamin D.// Just10 to 15 minutes of natural sunlight three ... factors can reduce sunlight exposure, such as windows, sunscreen, smog ...
... at the critical care centre felt that, everyone should ... response to infection. Sepsis occurs when the body over-reacts ... is associated with cancer but it can attack anyone.// ... pancreatic and prostate cancer together, and is the leading ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... many people with firm spiritual beliefs find it easier to ... relatives and friends of patients attending a hospice for terminal ... strong spiritual beliefs helped these people cope when their loved ... belief reported steady progress in coming to terms with their ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
Cached Medicine News:
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
... we believe that the trocar should be ... instrument precision and speeding the process. So ... trocar that meets the needs of the ... Xcel - The only trocar that affords ...
Medicine Products: